CSI Market
Sign In | Register

Cytokinetics Incorporated (CYTK) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access CYTK quarterly Cash Flow →
This cash flow overview for Cytokinetics Incorporated spans from Dec 31 2021 to Dec 31 2025, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-784.96
Depreciation & amortization10.13
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue-50.76
Restructuring Costs and Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation112.29
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest22.90
Non Cash Interest Expense-
Noncash Restructuring Charges-
Noncash Interest Expense-
Non Cash Interest Expense Related To Long Term Debt-
Interest Receivable And Amortization On Investments-15.98
Increase Decrease In Contract Assets-
Non Cash Interest Expense Related To Sale Of Future Royalties-
Non Cash Equity Related Expense-
Increase Decrease In Contract With Customer Asset-
Increase Decrease In Contract With Customer Liability-
Non Cash Interest Expense On Liabilities Related To Revenue Participant Right Purchase Agreement58.37
Derivative Gain Loss On Derivative Net-4.20
Liabilities Fair Value Adjustment0.20
Non Cash Lease Expense5.65
Debt Conversion Expense121.25
Right Of Use Asset Obtained In Exchange For Operating Lease Liability6.26
Increase Decrease In Operating Lease Liabilities-10.84
Increase Decrease In Operating Lease Liabilities-10.84
Income taxes0.00
Realized Investment Gains (Losses), Total-0.03
Increase (Decrease) in Accounts Receivable-1.11
Increase (Decrease) in Accounts Payable, Trade2.66
Increase (Decrease) in Accrued Liabilities33.60
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-2.93
Other Working Capital-6.25
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities4.58
Discontinued operations0.00
Net Cash flow from Operating Activities-510.01
Investing Activities
Capital Expenditures-24.81
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities1,109.65
Payments to Acquire Available-for-sale Securities, Debt-1,063.17
Real Estate Investments0.00
Investment In Non- Marketable Equity Security-5.00
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities16.67
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings729.46
Long-term debt - repayments-10.81
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock35.98
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-229.97
Proceeds From Initial And Subsequent Public Offering And Sale To Related Party Net Of Issuance Costs-
Proceeds From Draw Down Of Committed Equity Financing Facilities And At Market Facility Net Of Issuance Costs-
Proceeds From Other Issuances Of Common Stock And Warrants Net Of Issuance Costs-
Proceeds And Payments From Stock Based Award And Warrants Net Of Issuance Costs-
Proceeds From Sale Of Future Royalties Net Of Issuance Costs-
Proceeds From Issuance Of Common Stock Related To Sale Of Future Royalties Net Of Issuance Costs-
Proceeds And Payments From Stock Based Award Net Of Issuance Costs-
Proceeds From Convertible Notes Net Of Debt Discount And Issuance Costs-
Payment For Purchase Of Capped Call Options Associated With Convertible Notes-
Proceeds From Claims Settlements-
Proceeds From Issuance Of Underwritten Public Offering Of Common Stock Net-
Finance Lease Principal Payments-0.20
Proceeds From2020 Rpi Transactions Net-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities524.46
Effect of exchange rate on cash flow-0.72
Discontinued operations0.00
Free Cash Flow-534.82
Total Cash Flow30.40
4 historic quarters locked

Sign in to unlock the full Cytokinetics Incorporated cash flow history.

Sign In Create Free Account

About Cytokinetics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 26, 2026
  • Source: cytk-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-076495

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License